Pimco Corporate & Income Opportunity Fund 8-K, filed Aug 20, 2024
Pimco Corporate & Income Opportunity Fund (PTY)
About this 8-K
Pimco Corporate & Income Opportunity Fund filed this 8-K on August 20, 2024.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) August 20, 2024
PIMCO Corporate & Income Opportunity Fund
(Exact Name of Registrant as Specified in Its Charter)
Massachusetts
(State or Other Jurisdiction of Incorporation)
| 811-21238 | 466121513 | |
| (Commission File Number) | (IRS Employer Identification No.) | |
| 1633 Broadway, New York, NY | 10019 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
(844) 337-4626
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
| Common shares | PTY | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On August 15, 2024, the Board approved the removal of the Fund’s non-fundamental investment guideline for the Fund to invest at least 25% of the Fund’s total assets in corporate debt obligations and other corporate income-producing securities and approved the addition of a non-fundamental investment guideline for the Fund to invest at least 50% of the Fund’s total assets in corporate debt obligations and other corporate securities, effective September 20, 2024. The supplement to the Fund’s prospectus and statement of additional information disclosing this change is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits | |
| 99.1 | Supplement, dated August 20, 2024 | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PIMCO Corporate & Income Opportunity Fund | ||
| By: | /s/ Ryan G. Leshaw | |
| Name: | Ryan G. Leshaw | |
| Title: | Chief Legal Officer and Secretary | |
Date: August 20, 2024
PIMCO CORPORATE & INCOME OPPORTUNITY FUND
(the “Fund”)
Supplement dated August 20, 2024 to the
Fund’s Prospectus Supplement, Prospectus and
Statement of Additional Information, each dated September 28, 2023,
as supplemented from time to time
(respectively, the “Prospectus Supplement”, the “Prospectus” and the “SAI”)
On August 15, 2024, the Fund’s Board of Trustees (the “Board”) (i) approved the removal of the Fund’s non-fundamental investment guideline for the Fund to invest at least 25% of the Fund’s total assets in corporate debt obligations and other corporate income-producing securities and (ii) approved the addition of a non-fundamental investment guideline for the Fund to invest at least 50% of the Fund’s total assets in corporate securities. Accordingly, effective September 20, 2024:
1. In the “Portfolio Contents” section on the cover pages of the Prospectus, the third sentence of the first paragraph is replaced with the following:
The Fund normally invests at least 50% of its total assets in corporate debt obligations and other corporate securities, including fixed-, variable- and floating-rate bonds, debentures, notes and other similar types of corporate debt instruments, such as preferred shares, convertible securities, bank loans and loan participations and assignments, payment-in-kind securities, step-ups, zero-coupon bonds, bank capital securities, bank certificates of deposit, fixed time deposits and bankers’ acceptances, stressed debt securities, structured notes and other hybrid instruments, common stocks and other equity securities.
2. In the “Prospectus Summary—Portfolio Contents” section of the Prospectus and the “Portfolio Contents” section of the Prospectus, (i) the third sentence is deleted and (ii) the following language is added as the new fifth sentence:
The Fund normally invests at least 50% of its total assets in corporate debt obligations and other corporate securities, including fixed-, variable- and floating-rate bonds, debentures, notes and other similar types of corporate debt instruments, such as preferred shares, convertible securities, bank loans and loan participations and assignments, payment-in-kind securities, step-ups, zero-coupon bonds, bank capital securities, bank certificates of deposit, fixed time deposits and bankers’ acceptances, stressed debt securities, structured notes and other hybrid instruments, common stocks and other equity securities.
3. In the SAI, the first sentence of the first paragraph of the “Investment Objective and Policies—Corporate Debt Securities” is deleted and replaced with the following:
The Fund normally invests at least 50% of its total assets in corporate debt obligations and other corporate securities.
Investors Should Retain This Supplement for Future Reference
PTY_SUPP1_082024